Overview
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Eligibility
Inclusion Criteria:
- Have established ASCVD and/or CKD
Exclusion Criteria:
- Have type 1 diabetes
- Have had a major heart condition within 60 days prior to screening
- Have New York Heart Association Functional Classification Class IV heart failure